担载血管生长因子的乳液法纤维用于血管再生的研究

目的:制备担载血管生长因子(VEGF)的乳液法静电纺丝纤维膜,对其开展一系列表征,从而研究其血管再生的潜能。方法:通过W/O乳液法制备担载VEGF的静电纺丝纤维膜,并对其形态、力学性质进行表征。用VEGF ELISA分析方法对其体外释放动力学进行研究。运用CCK-8法检测乳液法静电纺丝纤维膜中VEGF的活性变化。结果:乳液法静电纺丝纤维膜呈现连通的三维网状结构,平均直径为1μm,模拟了细胞外基质(ECM),最大拉伸应力为3.03±0.66 M Pa,具有良好的抗拉伸能力,能够支持细胞的生长。乳液法纤维膜中VEGF在体外累积释放了14天,总释放量超过20000 pg,达到血管再生的有效浓度。CCK-8结果显示,乳液法纤维膜中的VEGF仍然保持较高的蛋白活性。结论:担载VEGF的乳液法静电纺丝纤维膜能够缓释出活性的蛋白,具有血管再生的潜能。     

担载神经生长因子(NGF)的乳液法涂层纤维体外缓释研究

目的:目前周围神经修复中,神经导管是研究热点,本文研究乳液法涂层纤维制备的神经导管在神经修复中应用的可能性。方法:本文采用乳液法制备担载NGF的丝素-聚乳酸(PLLA)涂层电纺纤维,观察纤维的形态,测定NGF的体外释放动力学参数,并考察纤维释放液对于PC12细胞增殖的影响。结果:担载NGF的涂层纤维具备类似于细胞外基质(ECM)的三维结构和多孔形态;涂层纤维中NGF体外有效缓释10天;细胞实验中,在含有释放液的培养基中生长的PC12细胞,与空白对照组相比,荧光强度平均多了2000-4000个荧光强度,所以释放液可以更好地促进PC12细胞的增殖。结论:担载NGF的乳液法涂层纺丝纤维具备促进缺损周围神经修复的条件,可以进一步研究在动物体内修复缺损周围神经中的效果,为以后的临床应用打下基础。     

乳液法神经生长因子（NGF）电纺纤维的体外研究

目的：使用乳液法制备含有神经生长因子（NGF）的电纺纤维,研究其外观形貌和机械强度等物理性能,以及制备过程中NGF活性的变化,纤维中NGF的担载量和纤维体外释放动力学,评价其能否成为理想的神经修复材料,为进一步将NGF电纺纤维应用于周围神经修复奠定基础。方法：将NGF水溶液分散于PLLA溶液,通过W／O乳液法制备静电纺丝缓释纤维,对纤维的外观形貌等物理性能等进行表征,使用Elisa方法测定制备过程中NGF活性的保持以及体外释放动力学。结果：NGF电纺纤维具备类似细胞外基质（ECM）的良好外观形貌和一定的机械强度,其中NGF活性保持19．58％士6．05％,体外有效释放11天。结论：本文制备的乳液法NGF电纺纤维具备良好的物理性能,能够持续缓释有效剂量的NGF,适合作为神经修复材料进行进一步研究。     

NGF电纺纤维的体外缓释研究

目的:研究担载神经生长因子(NGF)的静电纺丝纤维的表征,考察NGF电纺纤维对于周围神经修复的效果。方法:将NGF水溶液分散于PLLA溶液,通过W/O乳液法制备静电纺丝纤维,对纤维的形态、力学性能等进行表征,Elisa方法测定NGF的体外释放动力学,Alamer Blue法检测试剂来考察纤维释放液对于PC12细胞增殖的影响。结果:NGF电纺纤维具备良好的形态和力学性质,直径为500-900 nm,纤维具备三维多孔结构。纤维的最大拉伸应力为2.50±0.41 MPa。电纺纤维中NGF在体外可有效释放9天,累积释放量接近3000 pg。细胞活性实验结果显示,第1、3、5、7天释放液的荧光强度与对照组相比有显著差异。结论:担载NGF的乳液法静电纺丝纤维有促进缺损周围神经修复的潜质。     

静电纺丝制备担载神经生长因子的聚乳酸纤维的工艺研究

目的:研究担载神经生长因子(NGF)的聚乳酸纤维乳液法静电纺丝的制备工艺,从电压、溶液浓度等工艺条件进行探索,通过扫描电镜对纤维的形态结构进行观察,旨在找到最佳纺丝制备条件,并观察该条件下纤维的体外释放行为和细胞活性。方法:将NGF水溶液分散于聚乳酸(PLLA)溶液中,通过W/O乳液法制备静电纺丝纤维。分别从电压8 k V、10 k V、12 k V,浓度梯度90mg/m L、100 mg/m L、110 mg/m L进行静电纺丝纤维的制备,对纤维的形态等进行表征。使用ELISA对NGF体外释放动力学进行检测,用Alamer Blue试剂考察纤维释放液对于PC12悬浮细胞增殖的影响。结果:浓度和电压对电纺纤维制备影响很大。当浓度过大时,易堵塞纺丝喷头且纤维弯曲,过小时纤维粗细差异较大。电压过大或过小时纤维弯曲情况严重,甚至出现缠绕现象。当浓度为100 mg/m L,电压为10 k V时制备的乳液法静电纺丝聚乳酸纤维直径粗细均匀,具有较好形态。在该条件下的制备的纤维NGF体外有效释放13天,释放液可以促进PC12细胞的增殖。结论:担载NGF的聚乳酸纤维乳液法最佳静电纺丝制备条件为:PLLA溶液浓度100 mg/m L、电压10 k V,该条件下制备的担载NGF的聚乳酸纤维体外释放可累计释放13天,其释放液可有效促进PC12细胞的增殖,为进一步研究担载NGF的聚乳酸纤维导管奠定了一定的工艺基础。     

担载b-FGF的PLGA微球复合明胶支架的体外释放研究

目的:研究担载碱性成纤维细胞生长因子(b-FGF)微球复合明胶支架的外形特征、孔径、孔隙率及体外释放动力学,以期构建具有缓释功能、高孔隙率的担载细胞因子的新型复合明胶支架。方法:本文利用冷冻相分离法和S/O/W法先将b-FGF水溶液包裹于PLGA微球中,然后埋置于明胶溶液中制备为多孔复合明胶支架。分别对微球的形态和复合明胶支架的基本形态、孔径、孔隙率进行表征,通过Elisa法测定b-FGF在复合明胶支架中的体外释放行为。结果:制备成形态良好的三维复合明胶支架,其孔隙率为82.90%±1.45%,孔径范围为150~300μm,复合明胶支架中b-FGF在体外缓慢释放20余天。结论:担载蛋白微球复合明胶支架不仅满足组织工程支架的要求,还能有效缓释细胞因子,为细胞和组织生长提供良好的微环境,为进一步应用于组织工程领域提供了可能。     

装载于PLGA中的5-氟尿嘧啶缓释微球的制备及其体外释放的研究

目的:研究装载于不同分子量的PLGA中的5-氟尿嘧啶微球的制备方法及其在体外条件下的缓释行为。方法:以水包油包固复乳法将5-氟尿嘧啶包裹在高分子聚乳酸-聚羟基乙酸共聚物(PLGA)中,形成缓释微球,考察其大小,外观,包封率等理化性质,以紫外分光光度法为检测方法研究其体外释放行为。结果:经扫描电子显微镜观察,所制备的微球形态完整,大小较均匀。具有一定得包封率和载药量,体外释放研究表明其处方1和处方2的缓释时间为8天和23天。结论:以水包油包固复乳法制备的PLGA 5-氟尿嘧啶微球能够达到缓释的目的。     

蛋白药物涂层支架的制备表征与体外释放研究

目的:探讨将蛋白大分子药物以较高的担载量涂层于心脏支架,并在不发生蛋白聚集的前提下实现数周之久缓释的方法.方法:将牛血清白蛋白通过稳定的水相-水相乳液技术制备成多糖玻璃体颗粒,并将多糖玻璃体颗粒分散于聚乳酸溶液中喷涂于支架表面制成蛋白涂层支架,在37°CPBs中进行体外释放动力学研究,用SEC-HPLC比较了蛋白涂层支架制备前后蛋白的聚集情况,并用扫描电镜等对蛋白涂层支架表面进行了表征.结果:蛋白涂层支架在电镜观察下外观圆整,表面光滑,制剂过程中未产生蛋白聚集,且能从涂层中缓慢释放达50天以上.结论:稳定的水相-水相乳液技术及其基础上制备的蛋白多糖玻璃体颗粒应用于心脏支架涂层上,能在有效保护蛋白构象的同时实现蛋白的缓释,为具有抗再狭窄活性蛋白应用于心脏支架提供了技术平台.     

装载于PLGA中的5-氟尿嘧啶缓释微球的制备及其体外释放的研究

目的：研究装载于不同分子量的PLGA中的5-氟尿嘧啶微球的制备方法及其在体外条件下的缓释行为。方法：以水包油包固复乳法将5-氟尿嘧啶包裹在高分子聚乳酸-聚羟基乙酸共聚物（PLGA）中,形成缓释微球,考察其大小,外观,包封率等理化性质,以紫外分光光度法为检测方法研究其体外释放行为。结果：经扫描电子显微镜观察,所制备的微球形态完整,大小较均匀。具有一定得包封率和载药量,体外释放研究表明其处方1和处方2的缓释时间为8天和23天。结论：以水包油包固复乳法制备的PLGA 5-氟尿嘧啶微球能够达到缓释的目的。     

载阿霉素PLGA纳米微球的制备及性质研究

目的:制备新型癌症化疗制剂载阿霉素(Adriamycin)、聚乳酸-羟基乙酸共聚物(PLGA)纳米微球(ADM-PLGA-NP),研究其性质及体外释药特点。方法:以聚乳酸-羟基乙酸共聚物为包封材料,阿霉素为模型药物,采用复乳蒸发法制备ADM-PLGA-NP,扫描电镜观察微球形态,激光粒度分析仪检测粒径分布,紫外分光光度法计算载药率及包封率,体外药物释放实验考察微球对ADM的缓释作用。结果:ADM-PLGA-NP外观呈球形,平均粒径约(237±12.7)nm,载药量及包封率分别为(6.42±1.67)%和(53.82±8.34)%,药物在体外缓慢释放,5 d累积释放量达85%。结论:通过复乳蒸发法制备的ADM-PLGA-NP性质稳定,具有药物缓释性,有望成为一种新型的药物化疗载体。     

乳液法静电纺丝PLGA 组织工程缓释纤维的研究

目的:研究Dextran对蛋白药物的释放影响。方法:将模型蛋白BSA溶解于多糖溶液中,通过W/O乳液法静电纺丝制备缓释纤维。采用MicroBCA法测定该纤维体外释放行为,采用SEC-HPLC检测制备前后蛋白的聚集程度,并与不含多糖的BSA纤维做对照。结果:添加Dextran以后蛋白的包封率由52.68%提高到63.92%,第一天突释不大于药物载量的15%,对蛋白单体的保持达到85%以上。结论:Dextran可以改善一般组织工程纤维中蛋白药物的释放,提高蛋白药物在制剂、贮存、释放过程中的稳定性,增加纤维的载药量。     

静电纺丝纳米纤维体外释放与蛋白活性的研究

目的:通过选择不同的模型蛋白,探讨准确的研究静电纺丝纳米纤维支架的体外释放和快速的测定蛋白活性的方法.方法:通过O/W乳液法静电纺丝制备纳米纤维,并用扫描电镜对纳米纤维表面进行了表征.以GM-CSF为模型蛋白,采用ELISA双抗体夹心法考察纤维的体外释放行为;以BSA为模型蛋白,用SEC-H-PLC比较纤维制备前后蛋白的聚集情况;以β-半乳糖苷酶为模型蛋白,用ONPG法比较纤维制备前后酶的催化活性.结果:纤维表面平滑,直径均一,呈现互相连通的三维网状结构.纤维在5天内释放90％以上;纤维中回收的BSA单体比例为66.53％;β-半乳糖苷酶在纤维中的催化活性保持原活性的3.37％.结论:通过选择不同的模型蛋白,能够准确的测定静电纺丝纤维的体外释放,快速的考察纤维中的蛋白活性,对于更好的研究蛋白药物纳米纤维支架具有重要的参考价值.     

Fabrication,Characterization and Cellular Compatibility of Poly(Hydroxy Alkanoate) Composite Nanofibrous Scaffolds for Nerve Tissue Engineering

Tissue engineering techniques using a combination of polymeric scaffolds and cells represent a promising approach for nerve regeneration. We fabricated electrospun scaffolds by blending of Poly (3-hydroxybutyrate) (PHB) and Poly (3-hydroxy butyrate-co-3- hydroxyvalerate) (PHBV) in different compositions in order to investigate their potential for the regeneration of the myelinic membrane. The thermal properties of the nanofibrous blends was analyzed by differential scanning calorimetry (DSC), which indicated that the melting and glass temperatures, and crystallization degree of the blends decreased as the PHBV weight ratio increased. Raman spectroscopy also revealed that the full width at half height of the band centered at 1725 cm⁻¹ can be used to estimate the crystalline degree of the electrospun meshes. Random and aligned nanofibrous scaffolds were also fabricated by electrospinning of PHB and PHBV with or without type I collagen. The influence of blend composition, fiber alignment and collagen incorporation on Schwann cell (SCs) organization and function was investigated. SCs attached and proliferated over all scaffolds formulations up to 14 days. SCs grown on aligned PHB/PHBV/collagen fibers exhibited a bipolar morphology that oriented along the fiber direction, while SCs grown on the randomly oriented fibers had a multipolar morphology. Incorporation of collagen within nanofibers increased SCs proliferation on day 14, GDNF gene expression on day 7 and NGF secretion on day 6. The results of this study demonstrate that aligned PHB/PHBV electrospun nanofibers could find potential use as scaffolds for nerve tissue engineering applications and that the presence of type I collagen in the nanofibers improves cell differentiation.     

Endothelial differentiation of human stem cells seeded onto electrospun polyhydroxybutyrate/polyhydroxybutyrate-co-hydroxyvalerate fiber mesh

Tissue engineering is based on the association of cultured cells with structural matrices and the incorporation of signaling molecules for inducing tissue regeneration. Despite its enormous potential, tissue engineering faces a major challenge concerning the maintenance of cell viability after the implantation of the constructs. The lack of a functional vasculature within the implant compromises the delivery of nutrients to and removal of metabolites from the cells, which can lead to implant failure. In this sense, our investigation aims to develop a new strategy for enhancing vascularization in tissue engineering constructs. This study's aim was to establish a culture of human adipose tissue-derived stem cells (hASCs) to evaluate the biocompatibility of electrospun fiber mesh made of polyhydroxybutyrate (PHB) and its copolymer poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHB-HV) and to promote the differentiation of hASCs into the endothelial lineage. Fiber mesh was produced by blending 30% PHB with 70% PHB-HV and its physical characterization was conducted using scanning electron microscopy analysis (SEM). Using electrospinning, fiber mesh was obtained with diameters ranging 300 nm to 1.3 μm. To assess the biological performance, hASCs were extracted, cultured, characterized by flow cytometry, expanded and seeded onto electrospun PHB/PHB-HV fiber mesh. Various aspects of the cells were analyzed in vitro using SEM, MTT assay and Calcein-AM staining. The in vitro evaluation demonstrated good adhesion and a normal morphology of the hASCs. After 7, 14 and 21 days of seeding hASCs onto electrospun PHB/PHB-HV fiber mesh, the cells remained viable and proliferative. Moreover, when cultured with endothelial differentiation medium (i.e., medium containing VEGF and bFGF), the hASCs expressed endothelial markers such as VE-Cadherin and the vWF factor. Therefore, the electrospun PHB/PHB-HV fiber mesh appears to be a suitable material that can be used in combination with endothelial-differentiated cells to improve vascularization in engineered bone tissues.     

The effect of insulin-like growth factor-I, relaxin and luteinizing hormone on vascular endothelial growth factor secretion by cultured endometrial stromal cells on different days of early pregnancy in pigs

The effect of insulin-like growth factor-I (IGF-I), relaxin (RLX) and luteinizing hormone (LH) on vascular endothelial growth factor (VEGF) in vitro secretion by endometrial stromal cells in pigs was investigated on days 10-12 and 20-22 of gestation. LH-stimulated stromal cell secretion of VEGF did not differ among tested days of early pregnancy. However, IGF-I- and RLX-mediated release of VEGF depended on the day of pregnancy. It seems that IGF-I and RLX may be considered as potent activators of VEGF-mediated angiogenesis in porcine endometrium, and their action may be more pronounced during maternal recognition of pregnancy.